Boswellia Serrata + Liposomes 50 ml Eliphe CA4

Distributor
Eliphe
Normal price
49,90 €
Reduced price
49,90 €
Normal price
0 €
Out of stock
Price per unit
The quantity must be greater than or equal to 1

Description

Articular and Digestive

Boswellia Serrata is a dietary supplement that acts at the joint and digestive level. Eliphe uses a 95% pure extract of boswellic acids.

Composition

Water, sunflower oil, ethanol, emulsifiers: lactic and citric esters of mono- and diglycerides of fatty acids and sugar esters, Boswellia Serrata extract

50 ml tinted glass bottle with pipette

Advice for use

20 to 40 drops in two or three takes outside of meals.

Clinical studies

Safayhi H, et al. Boswellic acids: novel, specific, nonredox inhibitors of 5-lipoxygenase. J Pharmacol Exp Ther 1992;261(3):1143-6.

Henderson WR. The role of leukotrienes in inflammation. Ann Intern Med 1994;121:684-97.

Hutchinson F, et al. 5-lipoxygenase. Ann Rev Biochem 1993;63:383-417.

Sailer E-R, et al. Characterization of acetyl-11-keto-b-boswellic acid and arachidonate-binding regulatory site of 5-lipoxygenase using photoaffinity labeling. Eur J Biochem 1998;256:364-8.

Effects of gum resin of Boswellia serrata in patients with chronic colitis. Planta Med 2001 Jul;67(5):391-5.

Efficacy and tolerability of Boswellia serrata extract in treatment of osteoarthritis of knee - a randomized double blind placebo controlled trial. Phytomedicine 2003 Jan;10(1):3-7.

Search

This scientific text examines how frankincense preparations, in particular an extract called Boswellin Super® (BSR) containing a high concentration of 3-O-acetyl-11-keto-β-boswellic acid (AKBA), influence the production of lipid mediators (LMs) in human immune cells. AKBA is known for its anti-inflammatory properties and its ability to modulate lipoxygenase (LOX) enzymes, thereby promoting the formation of lipid mediators specialized in resolving inflammation (SPM) rather than the production of pro-inflammatory leukotrienes.

The study used human monocyte-derived macrophages (MDM), neutrophils and neutrophil/platelet co-incubations to assess the effect of BSR on LM biosynthetic pathways. The results show that BSR suppresses the formation of pro-inflammatory 5-LOX products and increases the production of 12/15-LOX products and MPS, particularly when combined with omega-3 fatty acids such as docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA).

The authors conclude that BSR, particularly with the addition of DHA and EPA, promotes a shift in lipid mediators in innate immune cells from pro-inflammatory to pro-resolving, which may explain the anti-inflammatory actions of BSR observed in traditional treatments. This indicates a pharmacological potential for the treatment of inflammatory diseases without the detrimental effects on inflammation resolution presented by glucocorticoids and non-steroidal anti-inflammatory drugs.

See the complete site